Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
The objective of this review was to examine the role of adverse drug events (ADEs) caused by pharmacological interventions in cost-effectiveness models for diabetes mellitus, diabetic retinopathy, and diabetic macular edema. Guidelines for economic evaluation recognize the importance of including ADEs in the analysis, but in practice, consideration of ADEs in cost-effectiveness models seem to be vague. Inadequate inclusion of these harmful outcomes affects the reliability of the results, and the information provided by economic evaluation could be misleading. Reviewing whether and how ADEs are incorporated in cost-effectiveness models is necessary to understand the current practices of economic evaluation. Studies included were published between 2011-2022 in English, representing cost-effectiveness analyses using modeling framework for pharmacological interventions in the treatment of diabetes mellitus, diabetic retinopathy, or diabetic macular edema. Other types of analyses and other types of conditions were excluded. The databases searched included MEDLINE (PubMed), CINAHL (EBSCOhost), Scopus, Web of Science Core Collection, and NHS Economic Evaluation Database. Gray literature was searched via the National Institute for Health and Care Excellence, European Network for Health Technology Assessment, the National Institute for Health and Care Research, and the International Network of Agencies for Health Technology Assessment. The search was conducted on January 1, 2023. Titles and abstracts were screened for inclusion by 2 independent reviewers. Full-text review was conducted by 3 independent reviewers. A data extraction form was used to extract and analyze the data. Results were presented in tabular format with a narrative summary, and discussed in the context of existing literature and guidelines. A total of 242 reports were extracted and analyzed in this scoping review. For the included analyses, type 2 diabetes was the most common disease (86%) followed by type 1 diabetes (10%), diabetic macular edema (9%), and diabetic retinopathy (0.4%). The majority of the included analyses used a health care payer perspective (88%) and had a time horizon of 30 years or more (75%). The most common model type was a simulation model (57%), followed by a Markov simulation model (18%). Of the included cost-effectiveness analyses, 26% included ADEs in the modeling, and 13% of the analyses excluded them. Most of the analyses (61%) partly considered ADEs; that is, only 1 or 2 ADEs were included. No difference in overall inclusion of ADEs between the different conditions existed, but the models for diabetic retinopathy and diabetic macular edema more often omitted the ADE-related impact on quality of life compared with the models for diabetes mellitus. Most analyses included ADEs in the models as probabilities (55%) or as a submodel (40%), and the most common source for ADE incidences were clinical trials (65%). The inclusion of ADEs in cost-effectiveness models is suboptimal. The ADE-related costs were better captured than the ADE-related impact on quality of life, which was most pronounced in the models for diabetic retinopathy and diabetic macular edema. Future research should investigate the potential impact of ADEs on the results, and identify the criteria and policies for practical inclusion of ADEs in economic evaluation.
Identifiants
pubmed: 39054883
doi: 10.11124/JBIES-23-00511
pii: 02174543-990000000-00336
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on Behalf of JBI.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Roberts M, Russell LB, Paltiel DA, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health 2012;15:804–811.
Council of Europe. Glossary of terms related to patient and medication safety Committee of Experts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group on Safe Medication Practices. World Health Organization; 2005.
Skelly CL, Cassagnol M, Munakomi S. Adverse events [internet]. StatPearls Publishing; 2021 [cited 2023 Oct 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558963/.
Rodríguez-Monguio R, Otero M, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003;21(9):623–650.
Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296(13):716–721.
Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med 2017;376(3):203–205.
Sharma D, Aggarwal AK, Downey LE, Prinja S. National healthcare economic evaluation guidelines: a cross‐country comparison. Pharmacoecon Open 2021;5(3):349–364.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013: process and methods [internet]. 2013 [cited 2024 Jul 9]. Available from: Process and methods [PMG9]. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
Penaloza Ramoz MC, Barton P, Jowett S, Sutton AJ. A systematic review of research guidelines in decision-analytic modeling. Value Health 2015;18:512–529.
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force Report. Value Health 2016;19(6):704–719.
Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Séverac H, Crawford B, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force Report. Value Health 2019;22(3):267–275.
Craig D, McDaid C, Fonseca T, Stock C, Duffy S, Woolacott N. Are adverse effects incorporated in economic models? A survey of current practice. Value Health 2010;26(3):323–329.
Lu Y, Dai Z, Chang F, Wang L, He J, Shi P, et al. Whether and how disutilities of adverse events were used in the economic evaluation of drug therapy for cancer treatment. Pharmacoeconomics 2023;41(3):295–306.
Heather EM, Payne K, Harrison M, Symmons DPM. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-a drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics 2014;32(2):109.
Pearce A, Haas M, Viney R. Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review. Appl Health Econ Health Policy 2013;11(6):619–637.
Alam U, Asghar O, Azmi S, Malik RA. General aspects of diabetes mellitus. Handb Clin Neurol 2014;126:211.
Stafford LK, Cruz JA, Aali A, Abate MD, Abd ElHafeez S, Adane TD, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet (British edition) 2023;402(10397):203–234.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022;65(12):1925–1966.
Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. JCI insight 2017;2(14).
Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac. J Ophthalmol (Phila) 2018;7(1):28–35.
Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care 2016;39(9):1643–1649.
Iyer P, Albini TA. Drug-related adverse effects of antivascular endothelial growth factor agents. Curr Opin Ophthalmol 2021;32(3):191–197.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica 2017;237(4):185–222.
Schmier JK, Hulme-Lowe CK. Cost-effectiveness models in age-related macular degeneration: issues and challenges. Pharmacoeconomics 2016;34(3):259–272.
Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics 2014;32(1):15–27.
Henriksson M, Jindal R, Sternhufvud K, Bergenheim K, Sörstadius E, Willis M. A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmacoeconomics 2016;34(6):569–585.
Pesonen M, Kankaanpää E, Jylhä V. Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol. JBI Evid Synth 2022;20(12):3058–3066.
Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping reviews. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis [internet]. JBI; 2020 [cited 2023 Jul 31]. Available from: https://synthesismanual.jbi.global.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169(7):467–473.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Abushanab D, Al-Badriyeh D, Liew D, Ademi Z. First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis. Curr Probl Cardiol 2022;47(6):100852.
Abushanab D, Liew D, Marquina C, Al-Badriyeh D, Adema Z. Cost-effectiveness of empagliflozin and metformin combination versus standard care as first-line therapy in patients with type 2 diabetes mellitus. Endocr Pract 2022;28(1):16–24.
Bagepally BS, Chaikledkaew U, Youngkong S, Anothaisintawee T, Thavorncharoensap M, Dejthevaporn C, et al. Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in Indian healthcare payer’s perspective. Clinicoecon Outcomes Res 2021;13:897–907.
Bain SC, Hansen BB, Malkin SJP, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER Clinical Trial Programme. Diabetes Ther 2020;11(1):259–277.
Barnett AH, Arnoldini S, Hunt B, Subramanian G, Hoxer CS. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: a long-term cost-effectiveness analysis. Diabetes Obes Metab 2018;20(8):1921–1927.
Basson M, Ntais D, Ayyub R, Wright D, Lowin J, Chartier F. The cost-effectiveness of dulaglutide 1.5mg versus exenatide QW for the treatment of patients with type 2 diabetes mellitus in France. Diabetes Ther 2018;9(1):13–25.
Beaudet A, Palmer JL, Timlin L, Wilson B, Bruhn D, Boye KS, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14(3):357–366.
Becker F, Dakin HA, Reed SD, Li Y, Leal J, Gustavson SM. Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial. Diabetes Res Clin Pract 2022;183:109152.
Bennett H, Tank A, Evans M, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. Diabetes Obes Metab 2020;22(7):1047–1055.
Bergenheim K, Williams SA, Bergeson JG, Stern L, Sriprasert MUS. cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am J Pharm Benefits 2012;4(1):20–28.
Brown ST, Grima Grima D, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus. Clinical Therapeutics 2014;36(11):1576–1587.
Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. J Med Econ 2016;19(7):672–683.
Brändle M, Azoulay M, Greiner RA. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland. Int J Clin Pharmacol Ther 2011;49(3):217–230.
Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes — update. CADTH Optimal Use Report, No. 3.1A. 2013.
Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, et al. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. J Med Econ 2019;22(4):336–343.
Capehorn M, Hallén N, Baker-Knight J, et al. Evaluating the cost-effectiveness of once-weekly semaglutide 1mg versus empagliflozin 25mg for treatment of patients with type 2 diabetes in the UK setting. Diabetes Ther 2021;12(2):537–555.
Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Simón S, Oyagüez I. Cost-effectiveness analysis of exenatide versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus. Pharmacoecon Open 2020;4(2):277–286.
Cardoso C, Ramírez de Arellano A. Cost-effectiveness analysis of insulin detemir compared to neutral protamine Hagedorn (NPH) in patients with type 1 and type 2 diabetes mellitus in Portugal. J Diabetes Metab 2016;7(3.
Carvalho D, Costa C, Hallén N, Baker-Knight J, Hunt B. A long-term cost-effectiveness analysis of treatments for type 2 diabetes in Portugal: once-weekly semaglutide 1 mg versus once-daily empagliflozin 25 mg. Rev Port Endocrinol. Diabetes Metab 2021;16:1–2.
Chakravarty A, Rastogi M, Dhankhar P, Bell KF. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness modeling the US setting. J Med Econ 2018;21(5):497–509.
Chalk D, Pitt M, Stein K. Cost-effectiveness of bevacizumab for diabetic macular oedema. British Journal of Healthcare Management 2014;20(12):585–593.
Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med 2015;32(7):890–898.
Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK healthcare system perspective. BMC Health Serv Res 2015;32(7):890–898.
Cheng H, Wan X, Ma J. Cost-effectiveness of insulin degludec versus insulin glargine in insulin-naive Chinese patients with type 2 diabetes. Clin Ther 2019;41(3):445–455.
Chien CL, Chen YC, Malone DC, Peng YL, Ko Y. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin 2020;36(10):1619–1626.
Choi JG, Winn AN, Skandari R, Franco MI, Staab EM, Alexander J, et al. First-line therapy for type 2 diabetes with sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. A cost-effectiveness study. Ann Intern Med 2022;175(10):1392–1400.
Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. J Med Econ 2016;19(12):1127–1134.
Cui Z, Zhou W, Chang Q, Zhang T, Wang H, Meng X, et al. Cost-effectiveness of conbercept vs. ranibizumab for age-related macular degeneration, diabetic macular edema, and pathological myopia: population-based cohort study and Markov model. Front Med 2021;8:750132.
Cutino A, Green K, Kendall R, Moore PT, Zachary C. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study. Am J Manag Care 2015;21(4 Suppl):63–72.
Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet Med 2012;29(3):313–320.
Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P. Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting. Pharmacoeconomics 2016;34(9):953–966.
Dawound D, Fenu E, Higgins B. Basal insulin regimens for adults with type 1 diabetes mellitus: a cost-utility analysis. Value Health 2017;20(10):1279–1287.
Deerochanawong C, Vareesangthip K, Piyayotai D, Thongsuk D, Pojchaijongdee N, Permsuwan U. Cost-utility analysis of dapagliflozin as an add-on to standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in Thailand. Diabetes Ther 2021;12(7):1947–1963.
Dempsey M, Mocarski M, Langer J. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. J Med Econ 2018;21(11):1110–1118.
Dempsey M, Mocarski M, Langer J, Hunt B. IDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine U100 plus insulin aspart in the U.S. Endocr Pract 2018;21(9):796–804.
Deng J, Gu S, Shao H. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies. J Med Econ 2015;18(11):974–989.
Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2012;119(8):1679–1684.
Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m2. J Med Econ 2017;20(5):443–452.
Drummond R, Malkin S, Du Preez M. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): a short-term cost-effectiveness analysis in the UK setting. Diabetes Obes Metab 2018;20(10):2371–2378.
Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary E, et al. The cost-effectiveness of empagliflozin versus liraglutide treatment in people with type 2 diabetes and established cardiovascular disease. Diabetes Ther 2021;12(5):1523–1534.
Ehlers LH, Lamotte M, Ramos MC, Sandgaard S, Holmgaard P, Frary E, et al. The cost–effectiveness of oral semaglutide versus empagliflozin in type 2 diabetes in Denmark. J Comp Eff Res 2022;11(1):29–37.
Ehlers LH, Lamotte M, Ramos MC, Sandgaard S, Holmgaard P, Kristensen MM, et al. The cost-effectiveness of subcutaneous semaglutide versus empagliflozin in type 2 diabetes uncontrolled on metformin alone in Denmark. Diabetes Ther 2022;13(3):489–503.
Ekhlasi M, Taheri S, Yousefi N. Cost-effectiveness of dulaglutide versus liraglutide for management of type 2 diabetes mellitus in Iran. Value Health Reg Issues 2022;32:54–61.
Elgart JF, Caporale JE, Gonzalez L, Aiello E, Waschbusch ME, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev 2013;3(1):11.
Eliasson B, Ericsson Å, Fridhammar A, Nilsson A, Persson S, Chubb B. Long‑term cost effectiveness of oral semaglutide versus empagliflozin and sitagliptin for the treatment of type 2 diabetes in the Swedish setting. Pharmacoecon Open 2022;6(3):343–354.
Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany. A Cardiff Diabetes Model Analysis. Clin Drug Investig 2012;32(3):189–202.
Ericsson Å, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16(12):1442–1452.
Ericsson Å, Glah D, Lorenzi M. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS One 2018;13(2):e0191953.
Ericsson Å, Fridhammar A. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden. J Med Econ 2019;22(10):997–1005.
Ericsson Å, Lundqvist A. Cost effectiveness of insulin degludec plus liraglutide (IDegLira) in a fixed combination for uncontrolled type 2 diabetes mellitus in Sweden. Appl Health Econ Health Policy 2017;15(2):237–248.
Escobar C, Morales C, Capel M, Simón S, Pérez-Alcántara F, Pomares E. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Serv Res 2022;22(1):217.
Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin – from the UK health care cost perspective. Diabetes Obes Metab 2014;16(4):366–375.
Evans M, Wolden M, Gundgaard J. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18(1):56–68.
Evans M, Gundgaard J, Bekker Hansen B. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in patients with type 2 diabetes from a Danish health-care perspective. Diabetes Ther 2016;7(4):809–823.
Evans M, Chubb B, Gundgaard J. Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus. Diabetes Ther 2017;8(2):275–291.
Evans M, Mehta R, Gundgaard J, Chubb B. Cost effectiveness of insulin degludec vs. insulin glargine u100 in type 1 and type 2 diabetes mellitus in a UK setting. Diabetes Ther 2018;9(5):1919–1930.
Evans M, Moes RGJ, Pedersen KS. Cost-effectiveness of insulin degludec versus insulin glargine u300 in the Netherlands: evidence from a randomised controlled trial. Adv Ther 2020;37:2413–2426.
Evans M, Chubb B, Malkin SJP, Berry S, Lawson J, Hunt B. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: a long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes Obes Metab 2023;25:491–500.
Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2 in Spain. J Med Econ 2013;16(7):926–938.
Franch-Nadal J, Malkin SJP, Hunt B, Martín V, Gallego Estébanez M, Vidal J. The cost-effectiveness of oral semaglutide in Spain: a long-term health economic analysis based on the PIONEER Clinical Trials. Adv Ther 2022;39(7):3180–3198.
Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag 2012;8:255–264.
Gæde P, Johansen P, Tikkanen CK, Pollock RF, Fulton R, Hunt B, et al. Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting. Diabetes Ther 2019;10(4):1297–1317.
Gao L, Zhao F, Li S. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;8(4):436–444.
Goh SY, Tan SC, Lim LC, Chua B, Hunt B. Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. J Diabetol 2015;6(1):2.
Goodall G, Costi M, Timlin L, Reviriego J, Sacrista´n JA, Smith-Palmer J, et al. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinol Nutr 2011;58(7):331–340.
Gordon J, McEwan P, Hurst M. The cost-effectiveness of alogliptin versus sulfonylurea as add-on therapy to metformin in patients with uncontrolled type 2 diabetes mellitus. Diabetes Ther 2016;7(4):825–845.
Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BHR. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. J Med Econ 2016;19(12):1167–1174.
Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab 2017;19:644–653.
Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin. J Med Econ 2020;23(2):193–203.
Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsapas A, Kourlaba G, Papageorgiou G, et al. Cost-effectiveness of empagliflozin for the treatment of patients with type 2 diabetes mellitus at increased cardiovascular risk in Greece. Clin Drug Investig 2018;38(5):417–426.
Gourzoulidis G, Tzanetakos C, Ioannidis I, Tsimihodimos V, Diogo V, Karpouzos G, et al. Cost‑effectiveness of empagliflozin compared with dapagliflozin for the treatment of patients with type 2 diabetes mellitus and established cardiovascular disease in Greece. Clin Drug Investig 2021;41(4):371–380.
Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Prim Care Diabetes 2012;6(2):127–136.
Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol. Therap 2012;14(1):65–73.
Guillermin A, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ 2012;15(4):654–663.
Gupta V, Baabbad R, Hammerby E, Nicolajsen A, Shafie AA. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes. J Med Econ 2015;18(4):263–272.
Gu S, Deng J, Shi L, Mu Y, Dong H. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in type 2 diabetes in China. J Med Econ 2015;18(10):808–820.
Gu S, Mu Y, Zhai S, Zeng Y, Zhen X, Dong H, et al. Cost-effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China. PLoS One 2016;11(11):E0165629.
Gu S, Zeng Y, Yu D, Hu X, Dong H, Hu C. Cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China. PLoS One 2016;11(11):e0167190.
Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes Obes Metab 2017;19(12):1688–1697.
Gu S, Shi L, Shao H, Wang X, Hu X, Gu Y, et al. Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Med 2020;18(1):378.
Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Manag Care Spec Pharm 2021;27(4):455–468.
Haig J, Barbeau M, Ferreira A. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema. J Med Econ 2016;19(7):663–671.
Haldrup S, Lapolla A, Gundgaard J, Wolden ML. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy. J Med Econ 2020;23(3):271–279.
Han G, Hu S, Zhang X, Qiu Z, Huang Z. Insulin degludec/liraglutide versus its monotherapy on T2D patients: a lifetime cost-utility analysis in China. Front Pharmacol 2022;13:1011624.
Holekamp N, Duff SB, Rajout Y, Garmo V. Cost-effectiveness of ranibizumab and afilbercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data. J Med Econ 2020;23(3):287–296.
Home P, Baik SH, Gálvez GG, Malek R, Nikolajsen A. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes. J Med Econ 2015;18(3):230–240.
Hou X, Wan X, Wu B. Cost-effectiveness of canagliflozin versus dapagliflozin added to metformin in patients with type 2 diabetes in China. Front Pharmacol 2019;10:480.
Huang K, Wang Y, Sun S, Zhu Q, Zhou W, Liu J, et al. Cost-effectiveness analysis of dapagliflozin plus standard treatment for patients with type 2 diabetes and high risk of cardiovascular disease in China. Front Public Health 2022;10:936703.
Huetson P, Palmer JL, Levorsen A, Fournier M, Germe M, McLeod E. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ 2015;18(8):573–585.
Hunt B, Glah D, van der Vliet M. Modeling the long-term cost-effectiveness of IDegLira in patients with type 2 diabetes who are failing to meet glycemic targets on basal insulin alone in the Netherlands. Diabetes Ther 2017;8(4):753–765.
Hunt B, Kragh N, McConnachie CC, Ceilidh C, Valentine WJ, Rossi M, et al. Long-term cost-effectiveness of two GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus in the Italian setting: liraglutide versus lixisenatide. Clin Ther 2017;39(7):1347–1359.
Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. J Med Econ 2017;20(7):663–670.
Hunt B, Mocarski M, Valentine WJ, Langer J. IDegLira versus insulin glargine U100: a long-term cost-effectiveness analysis in the US setting. Diabetes Ther 2017;8(3):531–544.
Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes Obes Metab 2017;19(6):842–849.
Hunt B, Ye Q, Valentine WJ, Ashley D. Evaluating the long-term cost-effectiveness of daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the United Kingdom. Diabetes Ther 2017;8(1):129–147.
Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel B. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care 2019;7(1):e000705.
Hu S, Deng X, Ma Y, Li Z, Wang Y, Wang Y. Cost‑utility analysis of dapagliflozin versus saxagliptin treatment as monotherapy or combination therapy as add‑on to metformin for treating type 2 diabetes mellitus. Appl Health Econ Health Policy 2021;19(1):69–79.
Hu S, Su X, Deng X, Wang Y. Exploring the appropriate price of semaglutide for type 2 diabetes patients based on cost-utility analysis in China. Front Pharmacol 2021;12:701446.
Hu S, Gu S, Qi C, Wang S, Qian F, Shi C, et al. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obes Metab 2023;25(2):387–297.
Hu S, Wang S, Qi C, Gu S, Shi C, Mao L, et al. Cost-utility analysis of once-weekly semaglutide, dulaglutide, and exenatide for type 2 diabetes patients receiving metformin-based background therapy in China. Front Pharmacol 2022;13:831364.
Hutton DW, Stein JD, Glassman AR, Bressler NM, Jampol LM, Sun JK. Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2019;137(12):1424–1432.
Iannazzo S, Mannucci E, Reifsnider O, Maggioni AP. Cost-effectiveness analysis of empagliflozin in the treatment of T2D with previous cardiovascular disease in Italy. Value Health 2017;20:480–481.
Igarashi A, Maruyama-Sakurai K, Kubota A, Akiyama H, Yajima T, Kohsaka S, et al. Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. Diabetes Ther 2022;13(7):1367–1381.
Ishii H, Madin-Warburton M, Strizek A. The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan. J Med Econ 2018;21(5):488–496.
Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. J Med Econ 2020;23(11):1311–1320.
Johansen P, Håkan-Bloch J, Liu AR, Bech PG, Persson S, Leiter LA. Cost effectiveness of once‑weekly semaglutide versus once‑weekly dulaglutide in the treatment of type 2 diabetes in Canada. Pharmacoecon Open 2019;3(4):537–550.
Johansen P, Chubb B, Hunt B, Malkin SJP, Sandberg A, Capehorn M. Evaluating the long-term cost-effectiveness of once weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK. Adv Ther 2020;37(5):2427–2441.
Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova AV, et al. Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME Trial. Clin Ther 2019;41(10):2021–2040.
Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, et al. Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med 2019;36(11):1494–1502.
Kiadaliri AA, Gerdtham UG, Eliasson B, Steen Carlsson K. Cost–utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine Hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther 2014;5(2):591–607.
Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 2011;183(16):1213–1220.
Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, et al. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Eff Resour Alloc 2016;14(7):7.
Kousoulakou H, Hatzikou M, Baroutsou V, Yfantopoulos J. Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece. Cost Eff Resour Alloc 2017;15(1):19.
Krishnamoorthy SG, Shaji JR, Premnath B, Siby AR, Borra SS, Manomohan A, et al. Cost-effectiveness analysis of dapagliflozin versus canagliflozin in treatment of type 2 diabetes mellitus. J Appl Pharm Sci 2022;12(3):171–178.
Kvapil M, Prásný M, Holik P. Cost-effectiveness of IDegLira versus insulin intensification regimens for the treatment of adults with type 2 diabetes in the Czech Republic. Diabetes Ther 2017;8(6):1331–1347.
Lalic N, Russel-Szymczyk M, Culic M, Tikkanen CK, Chubb B. Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia. Diabetes Ther 2018;9(3):1201–1216.
Langer J, Wolden ML, Shimoda S. Short-term cost-effectiveness of switching to insulin degludec in Japanese patients with type 2 diabetes receiving basal–bolus therapy. Diabetes Ther 2019;10(4):1347–1356.
Landstedt-Hallin L, Gundgaard J, Ericsson Å, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin 2017;33(4):647–655.
Lasalvia P, Baquero L, Otalora-Esteban M, Castañeda-Cardona C, Rosselli D. Cost effectiveness of dulaglutide compared with liraglutide and glargine in type 2 diabetes mellitus patients in Colombia. Value Health Reg Issues 2017;14:35–40.
Lasalvia P, Gil-Rojas Y, García Á. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert Rev Pharmacoecon Outcomes Res 2022;22(6):955–964.
Lau E, Salem A, Chan JCN, So WY, Kong A, Lamotte M, et al. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis. Cost Eff Resour Alloc 2019;17(1):13.
Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011;27(5):897–906.
Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ 2012;15(2):28–37.
Lin J, Chang JS, Yannuzzi NA, Smiddy WE. Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy. Ophthalmol 2018;125(9):1393–1400.
Lin WQ, Cai Z, Chen T, Liu MB, Li N, Zheng B. Cost-effectiveness of dipeptidylpeptidase-4 inhibitors added to metformin in patients with type 2 diabetes in China. Front Endocrinol (Lausanne) 2021. 12.
Lin GA, Brouwer E, Nikitin D, Moradi A, Chen Y, Herron-Smith S, et al. Tirzepatide for type 2 diabetes; final report [internet]. Institute for Clinical and Economic Review; 2022 [cited 2024 07 09]. Available from: https://icer.org/assessment/diabetes-type-2-2022/#timeline.
Liu L, Ruan Z, Ung C, Zhang Y, Shen Y, Han S, et al. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. Diabetes Ther 2023;14(1):93–107.
Luo Q, Zhou L, Zhou N, Hu M. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes. Front Public Health 2022;10:1016937.
Malkin SJP, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B. Once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes: a long-term cost-effectiveness analysis in Estonia. Diabetes Ther 2019;10(1):159–176.
Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B. the management of type 2 diabetes with once-weekly semaglutide versus dulaglutide: a long-term cost-effectiveness analysis in Slovakia. Adv Ther 2019;36(8):2034–2051.
Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract 2021;175:108759.
Malkin SJP, Carvalho D, Costa C, Conde V, Hunt B. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetol Metab Syndr 2022;14(1):32.
Martín V, Vidal J, Malin SJP, Hallén N, Hunt B. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the Spanish setting. Adv Ther 2020;37(10):4427–4445.
McCrimmon RJ, Falla E, Sha JZ, Alsaleh AJO, Lew E, Hudson R, et al. Cost-effectiveness of iGlarLixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the UK. Diabetes Ther 2021;12(12):3217–3230.
McCrimmon RJ, Lamotte M, Ramos M, Alsaleh AJO, Souhami E, Lew E. Cost-effectiveness of iGlarLixi versus iDegLira in type 2 diabetes mellitus inadequately controlled by GLP-1 receptor agonists and oral antihyperglycemic therapy. Diabetes Ther 2021;12(12):3231–3241.
McCrimmon RJ, Palmer K, Alsaleh AJO, Lew E, Puttanna A. Cost-effectiveness of iGlarLixi versus Premix BIAsp 30 in patients with type 2 diabetes suboptimally controlled by basal insulin in the UK. Diabetes Ther 2022;13(6):1203–1214.
McEwan P, Bennett H, Khunti K, Wilding J, Endmonds C, Thuresson M, et al. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab 2020;22(12):2364–2374.
McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause‐Nilsson IAM, Bhatt DL, et al. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab 2021;23(4):1020–1029.
Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab 2020;22(1):107–115.
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S. Lixisenatide for type 2 diabetes mellitus patients inadequately controlled on oral antidiabetic drugs: a mixed-treatment comparison meta-analysis and cost–utility analysis. Diabetes Ther 2020;11(8):1745–1755.
Men P, Liu T, Zhai S. Empagliflozin in type 2 diabetes mellitus patients with high cardiovascular risk: a model-based cost-utility analysis in China. Diabetes Metab Syndr Obes 2020;13:2823–2831.
Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther 2013;4(2):417–430.
Mezquita-Raya P, Darba J, Ascanio M, Ramírez de Arellano A. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective. Expert Rev Pharmacoecon Outcomes Res 2017;17(6):587–595.
Mezquita-Raya P, Ramírez de Arellano A, Kragh N, Vega-Hernandez G, Pöhlmann J, Valentine WJ, et al. Liraglutide versus lixisenatide: long-term cost-effectiveness of GLP-1 receptor agonist therapy for the treatment of type 2 diabetes in Spain. Diabetes Ther 2017;8(2):401–415.
Ming J, Zhang Y, Xu X, Zhao M, Wang Y, Chen Y, et al. Cost–effectiveness analysis of intravitreal aflibercept in the treatment of diabetic macular edema in China. J Comp Eff Res 2020;9(3):161–175.
Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012;96(5):688–693.
Montes Rodríguez P, Gabas JM, Esteban Floria O, Honrubia Grijalbo A, Ascaso Puyuelo FJ. Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema. Cost Eff Resour Alloc 2022;20(1):61.
Morales C, de Luis D, de Arellano AR, Ferrario MG, Lizán L. Cost-effectiveness analysis of insulin detemir compared to neutral protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain. Diabetes Ther 2015;6(4):593–610.
Morton JI, Marquina C, Shaw JE, Liew D, Polkinghorne KR, Ademi Z. Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia 2023;66:642–656.
Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-effectiveness of canagliflozin versus sitagliptin as add-on to metformin in patients with type 2 diabetes mellitus in Mexico. Value Health Reg. Issues 2015;8:8–19.
Neslusan C, Teschemaker A, Willis M, Johansen P, Vo L. Cost-effectiveness analysis of canagliflozin 300mg versus dapagliflozin 10mg added to metformin in patients with type 2 diabetes in the United States. Diabetes Ther 2018;9(2):565–581.
Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications 2018;32(2):210–215.
Nguyen-Thi HY, Nguyen NTQ, Le NDT, Beillat M, Ethgen O. Cost-effectiveness of gliclazide-based intensive glucose control vs. standard glucose control in type 2 diabetes mellitus. An economic analysis of the ADVANCE Trial in Vietnam. Front Public Health 2020;8:562023.
Nian H, Wan X, Ma J, Jie F, Wu B. Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Eff Resour Alloc 2020;18(1):12.
National Institute for Health and Care Excellence. Final appraisal determination. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). Published: September 2013. 1 Recommendations | Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | Guidance | NICE [2024 07 09].
National Institute for Health and Care Excellence. Ranibizumab for treating diabetic macular oedema. Technology appraisal guidance. Published: 27 February 2013. ranibizumab-for-treating-diabetic-macular-oedema-pdf-82600612458181 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes. Technology appraisal guidance. Published: 26 June 2013. dapagliflozin-in-combination-therapy-for-treating-type2-diabetes-pdf-82600679642821 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. Canagliflozin in combination therapy for treating type 2 diabetes. Technology appraisal guidance. Published: 25 June 2014. canagliflozin-in-combination-therapy-for-treating-type2-diabetes-pdf-82602428123077 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. Aflibercept for treating diabetic macular oedema. Technology appraisal guidance. Published: 22 July 2015. aflibercept-for-treating-diabetic-macular-oedema-pdf-82602611201221 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. Final appraisal determination Empagliflozin in combination therapy for treating type 2 diabetes. Published: January 2015. diabetes-type-2-empagliflozin-id641-final-appraisal-determination-document2 (nice.org.uk) [2024 07 09].
National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes. Technology appraisal guidance. Published: 26 June 2013. Updated 23 November 2016. dapagliflozin-in-combination-therapy-for-treating-type2-diabetes-pdf-82600679642821 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. Single technology appraisal sotagliflozin with insulin for treating type 1 diabetes [ID1376]. Committee Papers. NICE 2020. sotagliflozin-with-insulin-for-treating-type-1-diabetes-pdf-82609013897413 (nice.org.uk). [2024 07 09].
National Institute for Health and Care Excellence. TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema: evidence review. NICE 2022. ta349-dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema-evidence-review-pdf-14515028115397 (nice.org.uk) . [2024 07 09].
National Institute for Health and Care Excellence. Fast tract appraisal brolucizumab for treating diabetic macular oedema [ID3902]. Committee Papers. NICE 2022. committee-papers (nice.org.uk). [2024 07 09].
Nilsson K, Andersson E, Persson S, Karlsdotter K, Skogsberg J, Gustavsson S, et al. Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease. Diabetes Obes Metab 2023;25(3):748–757.
Nita ME, Eliaschewitz FG, Ribeiro E, Asano E, Barbosa E, Takemoto M. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Rev Assoc Med Bras 2012;58(3):294–301.
Pakdaman M, Akbari R, Dehghan HR, Asgharzadeh A, Namayandeh M. The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran. The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran. Int J Health Care Qual Assur 2020;33(4/5):323–331.
Pawaskar M, Bilir PS, Kowal S, Gonzalez C, Rajpathak S, Davies G. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes. Am J Manag Care 2019;25(5):231–238.
Pawaskar M, Bilir PS, Kowal S, Gonzalez C, Rajpathak S, Davies G. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. Diabetes Obes Metab 2019;21:1010–1017.
Pawaskar M, Bilir PS, Kowal S, Li Q, Weiss T, Davies G. Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetes. Am J Manag Care 2021;27(8):269–277.
Peng ZY, Yang CT, Ou HT, Kuo S. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: a model-based simulation analysis using 10-year real-world data and targeted literature review. Diabetes Obes Metab 2022;24(7):1328–1337.
Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain: 1.8 mg liraglutide versus sitagliptin. Diabetes Ther 2015;6(1):61–74.
Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S. Long-term cost-effectiveness of insulin glargine versus neutral protamine Hagedorn insulin for type 2 diabetes in Thailand. Appl Health Econ Health Policy 2016;14(3):281–292.
Permsuwan U, Dilokthornsakul P, Saokaew S, Thavorn K. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand. Clinicoecon Outcomes Res 2016;8:521–529.
Permsuwan U, Thavorn K, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective. J Med Econ 2017;20(9):991–999.
Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 2014;160(1):18–29.
Pesonen M, Kankaanpaa E, Vottonen P. Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: a Markov-model. Acta Ophthalmol 2021;99:1146–1153.
Pfohl M, Schädlich PK, Dippel FW, Koltermann KC. Health economic evaluation of insulin glargine vs NPH insulin in intensified conventional therapy for type 1 diabetes in Germany .. J Med Econ 2012;15(2):14–27.
Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN (R)) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Serv Res 2019;19(1):22.
Pöhlmann J, Montagnoli R, Lastoria G, Parekh W, Markert M, Hunt B. value for money in the treatment of patients with type 2 diabetes mellitus: assessing the long-term cost-effectiveness of IDegLira versus iGlarLixi in Italy. Clinicoecon Outcomes Res 2019;11:605–614.
Pöhlmann J, Russel-Szymczyk M, Holík P, Rychna K, Hunt B. Treating patients with type 2 diabetes mellitus uncontrolled on basal insulin in the Czech Republic: cost-effectiveness of IDegLira versus iGlarLixi. Diabetes Ther 2019;10(2):493–508.
Pollock RF, Valentine WJ, Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. J Med Econ 2011;14(1):36–46.
Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJA. UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin. Adv Ther 2012;29(12):1051–1066.
Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. J Med Econ 2012;15(4):766–775.
Pollock RF, Chubb B, Valentine WJ, Heller S. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes Metab Syndr Obes 2018;11:217–226.
Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, et al. DEVOTE 5: evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal-bolus regimens for type 2 diabetes in the UK. Diabetes Ther 2018;9(3):1217–1232.
Pollock RF, Heller S, Pieber TR, Woo V, Gundgaard J, Hallén N, et al. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: a Canadian setting (DEVOTE 9). Diabetes Obes Metab 2019;21(7):1706–1714.
Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M. A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for type 2 diabetes in Canada. J Comp Eff Res 2019;8(4):229–240.
Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, et al. Long-term cost-effectiveness of insulin degludec versus insulin glargine U100 in the UK: evidence from the basal-bolus subgroup of the DEVOTE Trial (DEVOTE 16). Appl Health Econ Health Policy 2019;17(5):615–627.
Pollock RF, Tikkanen CK. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. J Med Econ 2017;20(3):213–220.
Psota M, Psenkova MB, Racekova N, Ramírez de Arellano A, Vandebrouck T, Hunt B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Clinicoecon Outcomes Res 2017;9:749–762.
Ramos M, Foos V, Ustyugova A, Hau N, Gandhi P, Lamotte M. Cost-effectiveness analysis of empagliflozin in comparison to sitagliptin and saxagliptin based on cardiovascular outcome trials in patients with type 2 diabetes and established cardiovascular disease. Diabetes Ther 2019;10(6):2153–2167.
Ramos M, Cummings MH, Ustyugova A, Raza SI, de Silva SU, Lamotte M. Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK. Diabetes Ther 2020;11(9):2041–2055.
Ramos M, Ustyugova A, Hau N, Lamotte M. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in type II diabetes. J Comp Eff Res 2020;9(11):781–794.
Ramos M, Men P, Wang X, Ustyugova A, Lamotte M. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. Cost Eff Resour Alloc 2021;19(1):1–46.
Raya PM, Blasco FJA, Hunt B, Martin V, Thorsted BL, Basse A, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes Metab 2019;21(6):1349–1356.
Régnier SA, Malcolm W, Haig J, Xue W. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. Clinicoecon Outcomes Res 2015;7:235–247.
Reifsnider O, Kansal A, Pimple P, Aponte-Ribero V, Brand S, Shetty S. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States. Diabetes Obes Metab 2021;23(3):791–799.
Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care 2021;9(1.
Reifsnider OS, Pimple P, Brand S, Bergrath Washington E, Shetty S, Desai NR. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States. Diabetes Obes Metab 2022;24(4):652–661.
Ridderstråle M, Jensen MM, Gjesing RP, Niskanen L. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden. J Med Econ 2013;16(4):468–478.
Rind D, Guzauskas G, Fazioli K, Hansen R, Kumar V, Chapman R, et al. Oral semaglutide for type 2 diabetes: effectiveness and value [internet]. Institute for Clinical and Economic Review. December 9, 2019 [cited 2024 Jul 09]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Diabetes_Final-Evidence-Report_120919-1.pdf
Risebrough NA, Baker TM, Zhang L, Ali SN, Radin M, Dang-Tan T. Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics. Clin Ther 2021;43(11):1812–1826.
Rojas G, Nunes A. Pharmacoeconomic analysis of sitagliptin/metformin for the treatment of type 2 diabetes mellitus: a cost-effectiveness study. Value Health Reg. Issues 2021;26:33–39.
Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol 2016;134(8):888–896.
Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, et al. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. J Med Econ 2016;19(2):121–134.
Ruan Z, Ung COL, Shen Y, Zhang Y, Wang W, Luo J, et al. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Ther 2022;13(10):1737–1753.
Russell-Jones D, Heller SR, Buchs S, Sandberg A, Valentine WJ, Hunt B. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting. Diabetes Obes Metab 2017;19(12):1773–1780.
Russel-Szymczyk M, Valov V, Savova A, Manova M. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria. BMC Endocr Disord 2019;19(1):132.
Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga (R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes 2015;9(1):39–47.
Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. Cost-effectiveness of canagliflozin versus sitagliptin when added to metformin and sulfonylurea in type 2 diabetes in Canada. J Popul Ther Clin Pharmacol 2016;23(2):151–168.
Salem A, Men P, Ramos M, Zhang YJ, Ustyugova A, Lamotte M. Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with type 2 diabetes in China. J Comp Eff Res 2021;10(6):469–480.
Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ 2012;15(2):6–13.
Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2014;106(2):319–327.
Shafie AA, Ng CH. Cost-effectiveness of insulin glargine and insulin detemir in the basal regimen for naïve insulin patients with type 2 diabetes mellitus (T2DM) in Malaysia. Clinicoecon Outcomes Res 2020;12:333–343.
Shah D, Risebrough NA, Perdizet J, Iyer NN, Gamble C, Dang-Tan T. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. Clinicoecon Outcomes Res 2018;10:791–803.
Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, et al. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin 2017;33(2):359–369.
Shao H, Alsaleh AJO, Dex T, Lew E, Fonseca V. Cost effectiveness of iGlarLixi versus Premix BIAsp 30 in people with type 2 diabetes suboptimally controlled by basal insulin in the US. Diabetes Ther 2022;13(9):1659–1670.
Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. J Med Econ 2012;15(5):977–986.
Stafford S, Bech PG, Fridhammar A, Miresashvili N, Nilsson A, Willis M, et al. Cost‑effectiveness of once‑weekly semaglutide 1 mg versus canagliflozin 300 mg in patients with type 2 diabetes mellitus in a Canadian setting. Appl Health Econ Health Policy 2022;20(4):543–555.
Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagliptin. J Med Econ 2014;17(9):658–669.
Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120(9):1835–1842.
Su W, Li C, Zhang L, Lin Z, Tan J, Xuan J. Meta-analysis and cost-effectiveness analysis of insulin glargine 100 U/mL versus insulin degludec for the treatment of type 2 diabetes in China. Diabetes Ther 2019;10(5):1969–1984.
Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC. Cost-utility analysis of saxagliptin/dapagliflozin versus gliclazide and insulin glargine: economic implications of the outcomes of the CVD-Real Studies I and II. Health Serv Insights 2020;13.
Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res 2014;14:419.
Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig 2016;36(8):649–659.
Tzanetakos C, Bargiota A, Kourlaba G, Gourzoulidis G, Maniadakis N. Cost effectiveness of exenatide once weekly versus insulin glargine and liraglutide for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig 2018;38(1):67–77.
Valentine WJ, Aagren M, Haglund M, Ericsson Å, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scand J Public Health 2011;39(1):79–87.
Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther 2011;33(11):1698–1712.
Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med 2012;29(3):303–312.
Valentine WJ, Van Brunt K, Boye KS, Pollock RF. Treating type 1 diabetes mellitus with a rapid-acting analog insulin regimen vs. regular human insulin in Germany: a long-term cost-effectiveness evaluation. Appl Health Econ Health Policy 2018;16(3):357–366.
Van der Linden N, Van Olst S, Nekeman S, Uyl‐de Groot CA. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabet Med 2021;38:e14371.
van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 2014;34(2):135–146.
Vega-Hernandez G, Wójcik R, Schlueter M. Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK. Diabetes Ther 2017;8(3):513–530.
Viljoen A, Hoxer CS, Johansen P, Malkin S, Hunt B, Bain SC. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes Obes Metab 2019;21:611–621.
Viljoen A, Chubb B, Malkin SJP, Berry S, Hunt B, Bain SC. The long‑term cost‑effectiveness of once‑weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. Eur J Health Econ 2023;24(6):895–907.
Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, et al. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ 2014;17(7):499–507.
Wan B, Fang N, Guan W, Ding H, Wang Y, Ge X. Cost-effectiveness of bariatric surgery versus medication therapy for obese patients with type 2 diabetes in China: a Markov Analysis. J Diabetes Res 2019;2019:1341963.
Watada H, Sakamaki H, Yabe D, Yamamoto F, Murata T, Hanada K, et al. Cost-effectiveness analysis of linagliptin in Japan based on results from the Asian subpopulation in the CARMELINA Trial. Diabetes Ther 2020;11:1721–1734.
Yang L, Christensen T, Sun F, Chang J. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE Study. Value Health 2012;15(1):S56–S59.
Zhang X, Liu S, Li Y, Wang Y, Tian M, Liu G, et al. Long-term effectiveness and cost-effectiveness of metformin combined with liraglutide or exenatide for type 2 diabetes mellitus based on the CORE Diabetes Model Study. PLoS One 2016;11(6).
Zupa MF, Codario RA, Smith KJ. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for type 2 diabetes. J Comp Eff Res 2021;10(15):1133–1141.
McEwan P, Bennett H, Fellows J, Priaulx J, Bergenheim K, Pietropaolo M. The health economic value of changes in glycaemic control, weight and rates of hypoglycaemia in type 1 diabetes mellitus. PLoS One 2016;11(9.
McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc 2015;13(1):12.
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model. Value in Health 2014;17(6):714–724.
Hayes AJ, Leal J, Gray AM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013;56(9):1925–1933.
Lundqvist A, Steen Carlsson K, Johansen P, Andersson E, Willis M, Zhang H. Validation of the IHE cohort model of type 2 diabetes and the impact of choice of macrovascular risk equations. PLoS One 2014;9(10.
Wu B, Ma J, Zhang S, Zhou L, Wu H. Development and validation of a health policy model of type 2 diabetes in Chinese setting. J Comp Eff Res 2018;7(8):749–763.
Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM). PharmacoEconomics 2017;35(3):375–396.
Valentine WJ, Pollock RF, Saunders R, Bae J, Norrbacka K, Boye K. The Prime Diabetes Model: novel methods for estimating long-term clinical and cost outcomes in type 1 diabetes mellitus. Value Health 2017;20(7):985–991.
Eddy DM, Schlessinger L. Validation of the Archimedes Diabetes Model. Diabetes Care 2003;26(11):3102–3110.
Lauridsen JT, Lønborg J, Gundgaard J, Jensen HH. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res 2014;23(9):2645–2650.
Boye KS, Matza LS, Feeny DH, Johnston JA, Bowman L, Jordan JB. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches? Expert Rev Pharmacoecon Outcomes Res 2014;14(3):437–450.
Thielen FW, Van Mastrigt GAPG, Burgers LT, Bramer WM, Majoie HJM, Evers SMAA, et al. How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert Rev Pharmacoecon Outcomes Res 2016;16(6):705–721.